Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Reaches New 52-Week High - Should You Buy?

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report)'s stock price hit a new 52-week high during trading on Wednesday . The company traded as high as $11.23 and last traded at $11.02, with a volume of 34213 shares. The stock had previously closed at $11.15.

Analyst Upgrades and Downgrades

Separately, Deutsche Bank Aktiengesellschaft reissued a "buy" rating on shares of Fresenius SE & Co. KGaA in a report on Monday, February 3rd.

Fresenius SE & Co. KGaA Stock Down 0.2 %

The company has a current ratio of 1.36, a quick ratio of 1.05 and a debt-to-equity ratio of 0.57. The stock's fifty day moving average price is $9.99 and its 200 day moving average price is $9.39. The stock has a market cap of $24.11 billion, a P/E ratio of 51.38 and a beta of 1.02.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported $0.18 EPS for the quarter. The business had revenue of $6.01 billion for the quarter. As a group, research analysts forecast that Fresenius SE & Co. KGaA will post 0.79 earnings per share for the current fiscal year.

Fresenius SE & Co. KGaA Company Profile

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.